Duke Cancer Institute
Durham, North Carolina 27710-4000
41 studies enrolling now · 155 studies all time
What they study most
Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Adenocarcinoma, Pancreatic Ductal, Adolescent and Young Adult Cancer, Adolescent and Young Adult Cancer Patient, Adult Solid Tumor, Advanced Cancer, Advanced Malignancies, Advanced Malignant Neoplasm
Studies at this site
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) — Recruiting now
- Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) — Recruiting now
- A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer — Recruiting now
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer — Recruiting now
- Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer — Recruiting now
- A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer — Recruiting now
- A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations — Recruiting now
- A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC — Recruiting now
- Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer — Recruiting now
- A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy — Recruiting now
- A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis — Recruiting now
- A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer — Recruiting now
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors — Recruiting now
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment — Recruiting now
- A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). — Recruiting now
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
- A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer — Recruiting now
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) — Recruiting now
- Coping Skills Training for Symptom Management and Daily Steps (Step Up) — Recruiting now
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence — Recruiting now
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) — Recruiting now
- A Study of PHST001 in Advanced Solid Tumors — Recruiting now
- A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors — Recruiting now
- MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors — Recruiting now
- A Phase 1/1b Study of IAM1363 in HER2 Cancers — Recruiting now
- Family Building Decision Support for Female Adolescent and Young Adult Cancer Survivors — Recruiting now
- Improving Outcomes in Early Menopause After Cancer — Recruiting now
- Pilot Study of Mindset Moments Among Adolescent and Young Adult Cancer Survivors — Recruiting now
- Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy — Recruiting now
- ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) — Recruiting now
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation — Recruiting now
- A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer — Recruiting now
- Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms — Recruiting now
- Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors — Recruiting now
- A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors — Recruiting now
- Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors — Recruiting now
- Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma — Recruiting now
- Optimizing Surgical Decisions in Young Adults With Breast Cancer — Recruiting now
- Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration — Recruiting now
- Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy — Completed
- Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — Available (expanded access)
- Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer — Available (expanded access)
- Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. — Running, not enrolling
- Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases — Running, not enrolling
- Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer — Running, not enrolling
- First-in-Human Study of TAK-280 in Participants With Solid Tumors — Stopped early
- Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) — Stopped early
- A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101) — Starting soon
- Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer — Running, not enrolling
- Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. — Completed